Newly identified bone matrix protein may help treat osteosarcoma

A study published in the Journal of Orthopaedic Research has identified a bone matrix protein called Secreted phosphoprotein 24 kD (Spp24) that may help to treat osteosarcoma, the most common type of bone cancer.

In experiments conducted in cells and mice, investigators found that Spp24 inhibits the proliferation and invasiveness of osteosarcoma tumor cells and promotes their apoptosis, or death. Mechanistically, Spp24 binds to and neutralizes a protein called bone morphogenetic protein 2, which has tumor enhancing properties.

Spp24 and its proteolytic products have a number of effects on bone metabolism that have been elucidated to various degrees. They have the potential to be engineered into bone therapeutics, and this anti-tumor effect through bone morphogenetic protein 2 sequestration is only one such example. Like many other bone matrix proteins, the more we look into the function of Spp24, the more surprising roles we find even though the primary function of Spp24 remains uncertain."

Haijun Tian, MD, PhD, Co-Corresponding Author, Shanghai Jiao Tong University School of Medicine

 

Source:
Journal reference:

Chen, H., et al. (2023) Secreted phosphoprotein 24 kD (Spp24) inhibits the growth of human osteosarcoma through the BMP‐2/Smad signaling pathway. Journal of Orthopaedic Research. doi.org/10.1002/jor.25517.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Nomic® and Parker Institute for Cancer Immunotherapy (PICI) launch large-scale protein profiling to investigate immunotherapy responses in RADIOHEAD study